EULAR 2025 highlights… EULAR 2025 Highlights – Spondyloarthritis: Clinical (therapeutic) 18 Jul 2025 Superior effectiveness and comparable drug retention of anti-TNF therapy versus anti-IL-17A in ankylosing spondylitis after first anti-TNF failure: A propensity score-matched analysis from the Czech ATTRA Registry Abstract format and…
Spondyloarthritis II - therapeutic EULAR 2025: Do Not Miss – Spondyloarthritis II – therapeutic 1 Jun 20259 Jun 2025 Piotr KuszmierszCountry: Poland Piotr is a PhD in Medical Sciences and an Internal Medicine Specialist, currently undertaking his rheumatology training at the Department of Rheumatology and Immunology, Jagiellonian University Medical…
ACR Highlights… ACR Convergence 2024 Highlights – Spondyloarthritis: Clinical (therapeutic) 19 Dec 202419 Dec 2024 Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis Abstract format and assignment number: Poster 0540 Presenting author: J. Meade Aguilar (USA) Date: Saturday, 16th November 2024…
EULAR 2024 Highlights… EULAR 2024 Highlights – Spondyloarthritis II – therapeutic 21 Jul 202421 Jul 2024 Author: Jean-Guillaume Letarouilly Webers et al. (OP0060) investigated which ASDAS cut-off values correspond best with treatment intensification (TI) in practice through the prospective multicentre Dutch registry for patients with SpA…
Spondyloarthritis II - therapeutic EULAR 2024: Do Not Miss – Spondyloarthritis II – therapeutic 8 Jun 2024 Daliya PenchevaDaliya received her PhD focused on systemic lupus erythematosus management from the Medical University of Sofia, Bulgaria. Her major interests are patient-reported outcome measures, quality of life and treat-to-target strategies.…
ACR Highlights… ACR Convergence Highlights 2023 – Spondyloarthritis II: Clinical (therapeutic) 9 Dec 20239 Dec 2023 Author: Bayram Farisogullari Kivitz et al. (0776) investigated the long-term efficacy, safety, and tolerability of intravenous (IV) secukinumab (SEC) in patients with active PsA through 52 weeks in a randomised,…
Spondyloarthritis II - therapeutic [EULAR HL 2023] Spondyloarthritis II – therapeutic 20 Jun 2023 Author: Stefan Dinescu Baraliakos et al. (POS1106) studied the achievement of low disease activity in patients with axSpA treated with bimekizumab over 52 weeks. A greater proportion of patients with both nr-axSpA and r-axSpA obtained LDA at…
Spondyloarthritis II - therapeutic Spondyloarthritis II – Therapeutic 29 May 202329 May 2023 Renaud Felten Renaud is an Assistant Professor in the Clinical Investigation Center and the Department of Rheumatology of Strasbourg, France. His research interests include immunosuppressive drug and inflammatory rheumatic diseases,…
Spondyloarthritis II - therapeutic [ACR22] Spondyloarthritis II – Therapeutic 29 Nov 20226 Dec 2022 Author: Jean-Guillaume Letarouilly Baraliakos et al. (0420) studied the differences in the velocity and magnitude of NSAID response velocity in patients with established bDMARD naïve axSpA versus patients with other,…